Stock Price
332.92
Daily Change
1.68 0.51%
Monthly
-4.77%
Yearly
34.92%
Q1 Forecast
325.77

Alnylam Pharmaceuticals reported $777.57M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
BioCryst Pharmaceuticals USD 79.07M 6.61M Dec/2024
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Incyte USD 1.02B 128.52M Dec/2025
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Moderna USD 184M 862M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 8.98B 192M Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 397M 186.13M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Takeda JPY 757.92B 55.68B Dec/2025
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025
Xencor USD 29.3M 7.49M Dec/2025